Awarded with the 17th BBVA Foundation Frontiers of Knowledge Award in Biology and Biomedicine, physician and researcher Daniel J. Drucker explains how his pioneering work in the 1980s first revealed that GLP-1 stimulates insulin secretion, laying the groundwork for innovative therapies to treat type 2 diabetes. He highlights that these medications not only promote weight loss and lower the risk of hypoglycemia but also protect the heart, blood vessels, and kidneys, reducing heart attacks, strokes, and mortality. His current research explores GLP-1’s potential in neurodegenerative disorders, addictions, and inflammatory processes, with the goal of expanding global access to these transformative therapies.
The BBVA Foundation Frontiers of Knowledge Award in the Biology and Biomedicine category has gone in this seventeenth edition to Professors Daniel Joshua Drucker, Joel Habener, Jens J
Awarded with the 17th BBVA Foundation Frontiers of Knowledge Award in Biology and Biomedicine, physician and researcher Daniel J. Drucker explains how his pioneering work in the 1980s first revealed that GLP-1 stimulates insulin secretion, laying the groundwork for innovative therapies to treat type 2 diabetes. He highlights that these medications not only promote weight loss and lower the risk of hypoglycemia but also protect the heart, blood vessels, and kidneys, reducing heart attacks, strokes, and mortality. His current research explores GLP-1’s potential in neurodegenerative disorders, addictions, and inflammatory processes, with the goal of expanding global access to these transformative therapies.
The BBVA Foundation Frontiers of Knowledge Award in the Biology and Biomedicine category has gone in this seventeenth edition to Professors Daniel Joshua Drucker, Joel Habener, Jens Juul Holst and Svetlana Mojsov, “for their discovery and characterisation of the biologically active form of the hormone glucacon-like peptide (GLP-1)”
00:00 How has your research contributed to revealing the biological role and function of GLP-1?
00:53 In what ways have your discoveries led to new revolutionary treatments for both diabetes and obesity?
01:34 How have the new treatments based on your research helped to confront the social and economic burden of obesity and its related disorders?
02:32 Looking to the future, what further medical potential do you foresee for treatments based on GLP-1 to combat other diseases such as neurological disorders and addictions?
03:20 What are you working on now and what is your dream for the future development of the biomedical revolution launched by your discoveries?
